|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sandy Munro, PhD, Nikki Willis, and Geraldine Venthoye, PhD, believe selecting the delivery device/platform on the basis of patient needs, nature of disease, and opportunities for accelerating the proof-of-concept or early clinical stages by using fast-to-clinic approaches can help to accelerate the project through later-stage development by combining the approach with seamless scalability, designing in manufacturability, and an appropriate manufacturing strategy.
|
|
|
Darren Mansell says as early experience in following this guidance has recently matured, some issues have arisen that may impede best available outcomes for patients, one of which is the question of whether “interchangeability” guidance may stifle innovation (and therefore improved patient experience) in drug delivery devices.
|
|
|
Keith R. Horspool, PhD, Shirlynn Chen, PhD, and Markus Koester, PhD, discuss an open innovation platform to stimulate scientific understanding, and development of potential new technologies, for delivery of compounds with challenging solubility by offering a set of more contemporary poorly soluble drugs free-of-charge for independent research activities.
|
|
|
Laura Brand, Vice President of Celanese’s Medical & Pharmaceutical Business, discusses her company’s drug delivery platform and the value it brings to the industry.
|
|
|
|
|
|
|
|
|
 
Headquartered in the heart of the Swiss Alps, Datwyler Sealing Solutions is a leading industrial supplier and key player in global markets for system-critical components in healthcare, automotive, and general industry. The healthcare market segment provides state-of-the-art solutions for parenteral drug and medical device packaging. Datwyler Sealing Solutions is a leading manufacturer and a key player in the global healthcare world. Our state-of-the-art solutions for drug packaging and medical devices are built on over 100 years of experience. Click here for more.
 


|
|
|
|
|
|
 |
|
Context Therapeutics and Integral Molecular recently announced a research collaboration and licensing agreement for the development of an anti-claudin 6 (CLDN6) bispecific monoclonal antibody….
|
|
 |
|
AzurRx BioPharma, Inc. recently announced it has entered into an agreement with PPD, Inc. for its planned Phase 1b/2a clinical trial evaluating proprietary formulations of micronized….
|
|
 |
|
SOTIO recently announced new preclinical data of its antibody-drug conjugate (ADC), SOT102 (formerly SO-N102), for the treatment of solid tumors in a virtual….
|
|
 |
|
Artelo Biosciences, Inc. recently announced the first patient has been dosed in the company’s Phase 1/2 Cancer Appetite Recovery Study (CAReS) of ART27.13….
|
|
|
|
|
Upcoming eNewsletter Features:
April 28 – Formulation Development
May 5 – Prefilled Syringes
|
|
|
|
|
|
|
|